INBSHIGH SIGNALFINANCIAL10-K

INBS shows severe financial deterioration with cash plummeting 84% to just $1.0M despite revenue growing 949%, indicating potential liquidity crisis.

The dramatic cash burn from $6.3M to $1.0M alongside a 64% decline in stockholders' equity suggests the company is rapidly consuming capital despite achieving strong revenue growth. The combination of minimal cash reserves and continued capital requirements raises serious concerns about the company's ability to fund operations and meet financial obligations.

Comparing 2025-08-15 vs 2024-09-18View on EDGAR →
FINANCIAL ANALYSIS

While INBS achieved impressive 949% revenue growth from $189K to $2.0M, the financial picture is alarming as cash and equivalents collapsed 84% to just $1.0M and stockholders' equity fell 64% to $3.0M. The company appears to be burning through capital rapidly, with total assets declining 40% and current assets down 52%, suggesting significant liquidity stress despite operational improvements. The stark contrast between strong revenue growth and severe balance sheet deterioration indicates the company may be struggling to convert sales into sustainable cash generation.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+4218.9%
$5K$232K

Capital expenditure jumped 4218.9% — major investment cycle underway; assess returns on deployment.

Revenue
P&L
+949.3%
$189K$2.0M

Strong top-line growth of 949.3% — accelerating demand or successful expansion into new markets.

Cash & Equivalents
Balance Sheet
-83.8%
$6.3M$1.0M

Cash declined 83.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Stockholders Equity
Balance Sheet
-64%
$8.3M$3.0M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
-51.5%
$8.5M$4.1M

Current assets declined 51.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-40.1%
$13.8M$8.2M

Total assets contracted 40.1% — asset sales, write-downs, or balance sheet optimization underway.

Accounts Receivable
Balance Sheet
+38.4%
$430K$595K

Receivables surged 38.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Inventory
Balance Sheet
-18.3%
$778K$635K

Inventory reduced 18.3% — lean inventory management or demand outpacing supply.

Gross Profit
P&L
-12.5%
$1.4M$1.2M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2025-08-15
PRIOR — 2024-09-18
ADDED
As of August 12, 2025, there were 8,979,152 of the registrant s Common Stock issued and outstanding.
On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited ( IFP ), a company registered in England and Wales.
Our Testing Platforms Intelligent Fingerprinting Platform: The Company s current active product is the Intelligent Fingerprinting Platform, which consists of the proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader.
Biosensor Platform : Under the terms of an Amended and Restated License Agreement dated September 12, 2019 (the BPT License Agreement ), between the Company and Life Science Biosensor Diagnostics Pty Ltd ( LSBD or Licensor ), the Company held an exclusive license in the Asia Pacific Region ( APAC Region ) to the Licensor s proprietary rights to the biosensor technology (the Biosensor IP ) used in the biosensor platform we refer to as the Biosensor Platform Technology ( BPT ), or simply the Biosensor Platform .
This platform consists of a small, printable modified organic thin-film transistor strip designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte.
+7 more — sign up free →
REMOVED
As of September 16, 2024, there were 4,249,782 of the registrant s Common Stock issued and outstanding.
On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited ( IFP ), a company registered in England and Wales (the IFP Acquisition ).
The Company s current product portfolio includes: Intelligent Fingerprinting Platform: A proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader.
The Biosensor Platform A biosensor platform we refer to as the Biosensor Platform Technology ( BPT ), or simply the Biosensor Platform, consists of a small, printable modified organic thin-film transistor strip that we license across the Asia Pacific Region ( APAC Region ) from Life Science Biosensor Diagnostics Pty Ltd ( LSBD or Licensor ).
The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →